‘Unprecedented Times call for Bold Moves’ as Competitive Plasma Firms Unite to Battle COVID-19

‘Unprecedented Times call for Bold Moves’ as Competitive Plasma Firms Unite to Battle COVID-19

CSL Behring and Takeda Pharmaceutical Company have initiated an alliance bringing together the world’s leading plasma companies to focus on developing and delivering hyperimmune immunoglobulin to help fight the global war on COVID-19. Led by Australian and American and Japanese-headquartered life sciences firms, other participants include Biotest (Germany), LFB (France), and Octapharma (Switzerland). The alliance immediately commences with the investigational development of one, unbranded anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin medicine with the potential to treat individuals with serious complications from COVID-19.

The President of Takeda’s Plasma-Derived Therapies Business Unit,  Julie Kim, declared, “Unprecedented times call for bold moves.” Ms. Kim continued, “We collectively agree that by collaborating and bringing industry resources together we could accelerate bringing a potential therapy to market as well as increase the potential supply. We invite companies and institutions focusing on plasma support to join our alliance.” The group seeks to "accelerate a reliable, scalable and sustainable option for caregivers to treat patients suffering from the impact...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee